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ABSTRACT 
 
The objective of this study was the development of an accurate and sensitive method for the 
determination of gamma-hydroxybutyric acid (GHB) in dried whole blood samples using a GC-MS method. The 
complete procedure was optimized, with special attention for the sample pre-treatment, and validated. Therefore, 
dried blood spots (DBS) of only 50 µl were prepared and, after addition of internal standard GHB-d6, directly 
derivatized using 100 µl of a freshly prepared mixture of trifluoroacetic acid anhydride (TFAA) and 
heptafluorobutanol (HFB-OH) (2:1). The derivatized extract was injected into a gas chromatograph coupled to a 
mass spectrometer (GC-MS), operating in the electron impact mode (EI), with a total run time of 12.3 min. 
Method validation included the evaluation of linearity, precision, accuracy, sensitivity, selectivity and stability. 
A weighting factor of 1/x
2 
was chosen and acceptable intra-batch precision, inter-batch precision and accuracy 
were seen. The linear calibration curve ranged from 2 to 100 µg/ml, with a limit of detection of 1 µg/ml. Our 
procedure, utilizing the novel approach of direct “on spot” derivatization, followed by analysis with GC-MS, 
proved to be reliable, fast and applicable in routine toxicology. 
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1.  I1TRODUCTIO1 
 
Gamma-hydroxy butyric acid (GHB) is a short-chain fatty acid synthesized in the early sixties as an anaesthetic 
structure-analogue of gamma-amino butyric acid (GABA). Later on it was found to be endogenously present in 
mammalian brain tissue [1-3]. The function of GHB in humans is not completely understood, but experimental 
evidence suggests it may act as a neuromodulator or neurotransmitter [4]. GHB and its precursors gamma-
butyrolacton (GBL) and 1,4-butanediol (1,4-BD), which are converted into GHB within minutes after oral 
ingestion, are sold as a dietary supplement and used by bodybuilders as it is believed that GHB has a stimulatory 
effect on growth hormone production [5,6]. Although it has been abandoned as anaesthetic agent in most 
countries because of side effects such as seizures and coma, it is still registered in Germany (Somsanit®). The 
sodium salt of GHB, known under the international drug name sodium oxybate, has a role in the treatment of 
narcolepsy with cataplexy (Xyrem®) and of opiate and alcohol withdrawal (Alcover®) [7-11]. 
Currently, GHB as well as its precursors are popular as a party or club drug (“liquid ecstasy”) and appear 
occasionally in drug-facilitated sexual assaults (DFSA). This is due to their effects and chemical properties as 
they are colourless odourless liquids which can be easily mixed with other liquids [11-14]. GHB is mostly 
misused in combination with other drugs, such as alcohol, ecstasy (MDMA, XTC), cocaine, amphetamines and 
cannabis [12,13,15]. Most commonly reported effects of GHB abuse are euphoria, increased sexuality, well-
being and tranquillity, while an overdose results in seizures, respiratory depression, coma and sometimes even 
death [15-17]. The range between the desired effects and an overdose is narrow, frequently resulting in (non-) 
fatal intoxications in humans, as described in several case reports [18-24].  
Consequently, the identification and correct quantification of GHB is important in forensic and clinical 
toxicology. Many previously reported analytical methods detect GHB in different biological matrices and 
involve the use of gas chromatography (GC) [25-27], but also liquid chromatography (LC) [28,29] and capillary 
zone electrophoresis (CZE) [30]. Also the determination of GHB through headspace solid phase micro extraction 
(SPME) and dynamic extraction (SPDE) has recently been published [31,32].  
However, the determination of GHB in biological matrices remains an analytical challenge for several reasons. 
First, GHB is a small polar molecule, making its extraction and the direct detection with GC difficult. Hence, 
two approaches are generally used: besides the conversion of GHB in acidic conditions to GBL, which is more 
easily extracted from the biological matrix, the carboxyl and hydroxyl group can be derivatized, resulting in a 
more volatile and less polar compound. As derivatization technique, silylation is mostly used, but also alkylation 
and acylation have previously been described [25,27]. Furthermore, GHB occurs naturally in blood and urine, so 
no blank matrix is available and positive samples must be carefully interpreted. To enable the differentiation 
between exogenously-administered and endogenous GHB, cut-off levels have been proposed by several authors. 
These are currently set at 4 or 5 µg/ml for blood samples and 6 or 10 µg/ml for urine samples [33-36]. In 
addition, once orally ingested, GHB is rapidly metabolized, with a reported plasma half life of less than one 
hour. As this limits the detection window, plasma samples must be taken within 6 hours and urine samples 
within 12 hours (or better both within 6 hours) after ingestion [18]. 
In this study, we use dried blood spots (DBS) to improve the detection and quantification of GHB by facilitating 
sample collection. A DBS is capillary whole blood obtained by a finger or heel prick and collected on a filter 
paper. This sampling technique ensures an easy and rapid collection of a representative sample without specific 
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handling and storage requirements. These advantages as to a venipuncture make it a cost-effective choice for the 
collection, transport and storage of blood samples [37,38]. The DBS sampling method, originally used in 
newborn screening for metabolic disorders, is currently applied for the determination of various compounds such 
as biomarkers and is promoted for therapeutic drug monitoring (TDM). Already several compounds can be 
detected in DBS, most common are anti-malaria drugs, immunosuppressive drugs, anti-epileptics, antibiotics and 
anti-diabetics [38]. Inherent to DBS sampling is the small sample volume available, ranging from 10 to 200 µl, 
comparing to 1 ml or more obtained by a venipuncture. Although this may be an advantage when the collection 
of larger amounts of whole blood is limited, such as in neonates and children, these small amounts may impose 
an analytical challenge, requiring an efficient sample pre-treatment and a sensitive detection [39,40]. 
The determination of GHB in DBS may be interesting in situations where there is a suspicion of illicit use of 
GHB or one of its precursors, for example in case of driving under the influence of drugs (DUID) or a presumed 
DFSA.  As mentioned above, the short half life of GHB implies a limited detection window and, consequently, a 
rapid collection to obtain a representative sample. A delay caused by the need for a venipuncture by medical 
staff may bring the blood levels of GHB under the established cut-off levels. Moreover, no extraction step is 
necessary as DBS can be directly derivatized, minimizing the sample preparation and reducing the sample turn-
around time. Besides the advantages of a rapid collection, also storage of whole blood samples as DBS may be 
of interest as this may avoid in vitro formation of GHB, which has previously been reported [35,42]. Finally, 
even though DBS analyses are most commonly performed using LC-MS/MS, we opted to use GC-MS for 
several reasons. First of all, GC is a common and available technique in forensic laboratories, proven to be 
suitable for the detection of derivatized GHB with good sensitivity [25]. Secondly, given the low molecular 
weight of GHB, adequate and sensitive detection following liquid chromatography requires extensive sample 
pre-treatment, involving an extraction step and/or derivatization to enhance selectivity. So, the aim of this study 
was to develop and validate a GC-MS method for the identification and quantification of GHB in DBS, based on 
a new procedure, involving direct derivatization of GHB “on spot”, ensuring a minimal, economic and less time-
consuming sample pre-treatment.  
 
2. MATERIALS A1D METHODS  
 
2.1 Reagents 
 
2.1.1. Chemicals  
GHB (sodium salt) as powder and as a 1-mg/ml solution in methanol, as well as a 1-mg/ml solution in methanol 
of the internal standard (IS) GHB-d6 (sodium salt) were obtained from LGC standards (Molsheim, France).  The 
derivatization reagents heptafluorobutanol (HFB-OH) and trifluoroacetic acid anhydride (TFAA) were 
purchased from Sigma Aldrich (Steinheim, Germany).  Methanol and ethylacetate, both of suprasolve quality 
suitable for GC analysis, were delivered by Merck (Darmstadt, Germany).  
 
2.1.2. Stock and working solutions 
Stock and working solutions of GHB were prepared by dissolving 10 mg of the base in 1 ml of methanol, 
followed by appropriate dilution to obtain 1 and 0.1 mg base/ml methanolic solutions. Quality controls for all 
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analyses were obtained from the commercially available stock solution of 1 mg Na-GHB/ml methanol. For the 
IS, a solution of 0.05 mg base/ml was prepared starting from a 1-mg Na-GHB-d6/ml stock solution in methanol. 
All solutions were stored at -20 °C. 
 
2.2 Materials  
 
Protein saver cards number 903, used as sampling paper, were kindly provided by Whatman (ref n° 
WHA10334885, Dassel, Germany). The automatic lancets for capillary blood collection were purchased from 
Becton Dickinson (ref n° VAC366594, Franklin Lakes, USA), while the 50-µl precision capillaries were 
obtained from Servo-Prax (Wesel, Germany). The centrifuges used were a MSE Mistral 2000 (Beun de Ronde 
Serlabo, Anderlecht, Belgium) and a 5804R Eppendorf (Hamburg, Germany). Evaporation under nitrogen was 
conducted in a TurboVap LV evaporator from Zymark (Hopkinton, MA, USA).  
 
2.3 DBS sample collection 
 
Two methods are commonly used to obtain capillary whole blood on a filter paper. The drop of blood can be 
collected directly on the filter paper or with the aid of a precision capillary.  In this study, we opted to use the 
latter method, in which a drop with a fixed volume is spot onto the paper. As the complete drop can be excised 
instead of punching out a disk from it, the influence of sample volume, hematocrit and sampling technique is 
minimised [38].  
In the procedure to obtain a DBS, the hand is first cleaned and held down or warmed for a few minutes. With the 
help of an automatic lancet, the fingertip is pricked. While the first drop is wiped off with a sterile piece of cloth 
because of the presence of tissue fluid, the following drops are collected in a 50-µl precision capillary. Then, 
once completely filled, the entire capillary is placed in the centre of two concentric circles pre-printed on a 
Whatman 903 filter paper. The inner circle (10 mm diameter) must be entirely filled with blood, but blood may 
not pass the outer circle line (15 mm diameter), which was used for excision of the DBS. Although the blood is 
spot on just one side, both sides of the filter paper must be coloured. After visual inspection of the DBS, the 
analyzes can start [38].  
For method development and validation, we used 50-µl spots of venous whole blood from healthy non-user 
volunteers with endogenous GHB concentration below the established lower limit of quantification (LLOQ) and 
preserved for maximum one week at 4 °C. The DBS are dried for minimum 4 hours at ambient temperature and 
subsequently analyzed or preserved in a sealable plastic bag at room temperature or -20 °C until analysis.  
 
2.4 Optimization of the DBS sample preparation 
 
First, 10 µl of the IS solution was applied to a DBS and left to dry for 15 min. Subsequently, the spot was 
completely excised following the outer circle line, placed in a test tube and a freshly prepared mixture of TFAA 
and HFB-OH was added, followed by sonication for 5 min. Sabucedo and Furton [27] described the use of 1 ml 
of this mixture to derivatize GHB in aqueous samples (drinks) at 85 °C for 30 min, while we desired the 
derivatization of GHB in a biological matrix. For this purpose, the main critical parameters for derivatization, 
such as amount of reagent, temperature and time, were thoroughly evaluated. So, different amounts of 
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derivatization mixture were tested, respectively 75, 100 and 125 µl of a TFAA and HFB-OH (2:1) solution. Also 
derivatization temperatures varying from room temperature to 60, 70, 85 and 100 °C and derivatization times 
ranging from 5 to 30 min were tested. For each condition, at least 3 DBS spiked with GHB at a 10 µg/ ml 
concentration level were analyzed and the resulting absolute peak areas of derivatized GHB were compared.  
After the derivatization step, the DBS was cooled down by centrifugation for 5 min at 4 °C and evaporated to 
dryness under a gentle stream of nitrogen at 25 °C to remove excess of derivatization reagent. The dried sample 
was redissolved in 200 µl of ethylacetate, sonicated and centrifuged for 5 min at 1600 x g. Eighty-five µl was 
transferred, centrifuged again and finally 50 µl was transferred to a vial, of which 1 µl was injected into the GC-
MS.  
 
2.5 The analytical procedure 
 
Samples were analyzed on an Agilent 6890 GC system coupled to a 5973 mass-selective detector. Splitless 
injections were performed automatically at an injection temperature of 250 °C, a purge time of 1.5 min and 
helium was used as carrier gas at a constant flow rate of 1.3 ml/min.  A 30 m x 0.25 mm i.d. x 0.25 µm Varian 
VF-5-MS column (Varian; Middelburg, The Netherlands) was used. The temperature program was started at 60 
°C for 1.5 min, ramped at 10 °C/min to 110 °C, then raised by 50 °C/min to 300 °C, which was held for 2 more 
min for optimal column performance and maintenance, resulting in a total run time of 12.3 min. The transfer line 
temperature and ion source temperature were set at 280 and 230 °C, respectively. MS quadrupole temperature 
was set at 150 °C and ionization energy of 70 eV was used. The mass spectrometer operated in the selected ion 
monitoring (SIM) mode using electron impact ionization (EI) for quantification of GHB and GHB-d6. By 
running standards in full scan, typical mass spectra were obtained and following ions were monitored in the SIM 
mode: m/z 155, 183, 227 and 242 for derivatized GHB and m/z 161, 189, 231 and 245 for derivatized GHB-d6 
(underscored ions represent the quantifier ions, as these had the highest abundance; the other ions were selected 
as qualifier ions). 
 
2.6 Validation 
 
The following criteria were evaluated to validate the method: linearity, precision, accuracy, sensitivity, 
selectivity and stability [43-45].  
 
2.6.1 Linearity, precision, accuracy and sensitivity 
As no blank matrix is available, fresh venous human whole blood withdrawn on EDTA as anti-coagulant was 
used to prepare the calibration standard solutions. The concentration of endogenous GHB was tested to be below 
the LLOQ of the method (less than 2 µg/ml) and the ratio GHB to GHB-d6 was always lowered with the mean 
ratio of the zero samples (blank whole blood + IS, in duplicate) measured on each calibration day.  
A 5-point calibration curve was constructed six times on six different days. Each day a blank, 2, 10, 25, 50 and 
100 µg/ml solution of GHB in whole blood was prepared, as well as the QC solutions at low (2 µg/ml), medium 
(10 µg/ml) and high (100 µg/ml) concentration level, covering the whole calibration range. From each solution, 
50-µl spots were made, left to dry at room temperature for minimum 4 h, followed by analysis. The resulting 
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data were statistically evaluated and weighted if necessary, based on the sum % relative error (RE) and the % RE 
plot versus concentration, where % RE is the concentration found lowered with the nominal concentration, 
divided by the nominal concentration and multiplied by 100. Linearity was assessed by performing the Fisher-
test [43,46]. 
Intra-batch-precision was assessed by replicate analysis of spiked samples (n=5 at low, medium and high 
concentration level) in a single day, inter-batch-precision was evaluated by determination of spiked samples per 
concentration on 6 days. Precision was measured by calculating the relative standard deviation (RSD, SD 
divided by the mean and multiplied by 100 %). Also accuracy was determined for each concentration level, 
calculated by the percent deviation from the nominal concentration.  
For evaluation of sensitivity, the limit of detection (LOD) and the limits of quantification (LLOQ and ULOQ) 
were determined. The LOD was estimated as the minimum concentration of GHB with a signal-to-noise ratio 
equally or larger than 3, so with reliable differentiation of the background noise and in compliance with the 
identification criteria [46,47]. The lowest and highest concentration of GHB still measured with acceptable 
precision (RSD less than 20 % for LLOQ, 15 % for ULOQ) and accuracy (80-120 % for LLOQ, 85-115 % for 
ULOQ) were chosen as the LLOQ and ULOQ, respectively.  
Furthermore, possible dilution of the final extract of samples above the ULOQ was investigated. Therefore, 
human whole blood was spiked at 200 µg/ml (twice the ULOQ, in duplicate) and 50-µl spots were processed as 
described above (n=3). Ten µl of the final derivatized extract was diluted to 100 µl with ethyl acetate, analyzed 
by GC-MS and corrected for the dilution factor. Carry-over was also tested by injecting the highest concentration 
level of the calibration curve, followed by 3 blank (ethylacetate) injections.  
 
2.6.2 Selectivity 
The possible contribution of the isotopically labelled IS was assessed by analyzing both blank and zero (blank 
whole blood spiked with IS) samples. Furthermore, we investigated the possible interference of structural 
analogues such as beta-hydroxybutyric acid (BHB), alpha-hydroxybutyric acid (AHB) and GABA and the 
precursors GBL and 1,4-BD (spiked at 100 µg/ml); as well as the mainly co-ingested club and date-rape drugs 
(alcohol, cocaine, benzoylecgonine, ∆9-tetra-hydrocannabinol (THC), 11-nor-9-carboxy-THC, ketamine, 
flunitrazepam, XTC and amphetamine, spiked at or well above concentrations typically found in abusers). At 
least six different sources of whole blood were spiked and analyzed, in order to compare the ratio of GHB to 
GHB-d6 of blank samples, spiked at a known GHB concentration, with that of the samples containing the 
interferences. 
 
2.6.3 Stability  
As the filter paper matrix is expected to stabilize most analytes in DBS, we evaluated the stability of GHB in 
DBS stored at different conditions [37]. Therefore, three separate solutions in whole blood at both low (5 µg/ml) 
and high (100 µg/ml) concentration levels were prepared and the resulting spots were preserved in a sealable 
plastic bag at room temperature for one week, at 4 °C for 24 h and at -20 °C for 14 days. For the first 48 h at 
room temperature, DBS were analyzed after 2, 4, 8, 12, 24 and 48 h to assess the influence of drying time. The 
mean percentage found needs to be within 85 to 115 % of the results obtained when analyzed after 4 h of drying, 
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as this is the minimum drying time recommended by the manufacturer and therefore chosen as the reference time 
point. 
To assess the stability of the processed samples, extracts (low and high concentration level, in triplicate) were re-
injected after 24 h at room temperature and after storage for minimum one week at -20 °C (per concentration 
level, in duplicate).  The ratio of GHB to GHB-d6 was compared to this of the directly analyzed extract. Stability 
of stock solutions at two concentration levels (n=3) was assessed over 14 days at -20 °C and after three freeze-
thaw cycles.  
 
2.7 Application  
 
The described procedure was applied to blood samples of two young men suspected of GBL-intake, along with 
other drugs, to evaluate the routine applicability and the easiness of the method in a laboratory setting. The two 
young men were found on the street under influence, one was in critical condition, and were brought to a nearby 
hospital. Blood and urine samples were taken and sent to our laboratory for analysis of drugs and alcohol. As 
soon as the blood samples arrived at the laboratory, DBS were prepared and stored until analysis. Along with the 
DBS analysis, the blood samples were also subjected to routine toxicological analysis, involving screening by 
enzymatic assays and confirmation of positive results by high performance liquid chromatography - diode array 
detection (HPLC-DAD) and GC-MS.   
 
3. RESULTS A1D DISCUSSIO1 
 
3.1 Optimization of the DBS sample preparation 
 
Inherent to DBS sampling is the small sample volume available, necessitating an efficient sample preparation 
[39]. Therefore, different procedures were tested and compared to obtain the optimal conditions of extraction and 
derivatization of GHB, in order to work as sensitive as possible in an easy and time-saving way. 
Optimisation of the sample preparation resulted in the set-up of a quick and efficient protocol. Direct 
derivatization took place by adding 100 µl of a freshly prepared mixture of TFAA and HFB-OH (2:1) to a test 
tube containing the excised DBS. Then, the test tube was sonicated for 5 min, ensuring the distribution of the 
derivatization reagent [48] and placed in a heating block at 60 °C for 10 min. After cooling down, the sample 
was dried under a gentle stream of nitrogen at 25 °C. Next, the DBS was re-dissolved in 200 µl of ethyl acetate, 
sonicated and centrifuged two subsequent times, followed by transfer of an aliquot of the supernatant to a vial, of 
which 1 µl was injected into the GC-MS. The overall procedure from receipt of a DBS to a quantitative result 
can be completed in less than 2 h.  
As the polarity and the low molecular weight of GHB requires derivatization or conversion to GBL prior to GC 
analysis, we chose direct derivatization instead of conversion, thus avoiding extraction and resulting in an easier, 
less time-consuming sample preparation. Apart from a method previously published by our group, only one other 
published method utilizes direct derivatization of GHB [26,27]. However, both methods have as a major 
drawback that they require a considerably larger amount of derivatization reagent, around 1 ml for each sample, 
while here only 100 µl is needed, contributing to a more economic and environmentally-friendly procedure. 
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Déglon et al. recently published a method for the determination of antidepressants in DBS, with extraction using 
500 µl 0.02% triethylamine in butyl chloride, in combination with direct derivatization using 100 µl 
derivatization reagent [49]. However, to the best of our knowledge, our procedure is the first where 
derivatization reagents are applied directly “on spot” without the use of any extraction solvent. 
 
3.2 Analytical procedure and validation 
 
The optimized conditions for sample pre-treatment (heating the excised DBS for 10 min at 60°C with 100 µl of a 
freshly prepared mixture of TFAA and HFB-OH (2:1), followed by drying and redissolving in 200 µl ethyl 
acetate, see section 3.1), and analysis by GC-MS (as described in section 2.5) were carried out for validation of 
the method. 
 
3.2.1 Linearity, precision, accuracy and sensitivity 
To assess linearity, a blank, two zero (blank whole blood + IS) and 5 calibration samples were analyzed on six 
different days. Representative chromatograms of the injection of a derivatized extract of a blank DBS and a DBS 
containing GHB in a concentration at the lower end of the calibration curve (LLOQ) are shown in Fig. 1a and 
1b, respectively. Table 1a summarizes the calibration and sensitivity data. Ratios of GHB to GHB-d6 were 
calculated by dividing the peak area of GHB by the peak area of GHB-d6 and were lowered with the mean ratio 
of the zero samples. Results were statistically evaluated and a weighting factor 1/x
2 
was applied to the linear 
calibration curves. Also, the zero value was included in the 95 % confidence interval of the y-intercept, 
indicating absence of a constant error. As indicated in Table 1b, overall intra-, and inter-batch precision and 
accuracy were below 15 % and below 20 % at LLOQ level.  
To evaluate the ability to dilute samples with a GHB concentration above the ULOQ, replicate DBS of a 200 
µg/ml solution were analyzed as described in the materials and methods section. Following a 10-fold dilution of 
the derivatized extract, the concentration was back-calculated using daily calibration curves, and precision and 
accuracy were found to be within the acceptance limits of 15 %. No carry-over was seen following injection of a 
sample with GHB spiked at ULOQ level (less than 0.085 %). 
 
3.2.2 Selectivity 
The fact that preliminary studies indicated a small interference at the retention time of GHB by injection of a 
derivatized extract of a blank filter paper, combined with the endogenous presence of GHB in whole blood, 
rendered it impossible to prove lack of response of the blank matrix. However, as the paper signal and the signal 
of the used whole blood had a peak area below 10 and 20 % of that of the LLOQ, respectively, no unacceptable 
interferences were seen [45]. No unacceptable interferences were seen at the retention time of the IS either. 
When analyzing both blank and zero samples (the latter corresponding to blank + IS), no significant difference 
was seen in the mean response of GHB.  
To further evaluate selectivity, six different sources of whole blood were spiked with a combination of structure-
analogues of GHB, and certain club and date-rape drugs, with no interferences being observed. Not 
unexpectedly, the presence of a high concentration of GBL in the sample resulted in an increase of the GHB 
signal, likely due to conversion during sample preparation. The inter-conversion between GBL and GHB is well-
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known and has extensively been investigated. It can be influenced by pH, temperature and time [28,50-52]. 
Upon spiking increasing concentrations of GBL to whole blood, followed by analyzing the resulting DBS, we 
saw an approximate 10 % conversion of GBL to GHB, independent from the GBL concentration. This result is 
consistent with that reported by Sabucedo and Furton [27], who found a 6.5 % conversion. Because upon 
ingestion, GBL is metabolized to GHB by serum lactonases within minutes in humans, normally no or only 
minimal amounts of GBL will be present in the sample. However, possible saturation of serum lactonases 
following ingestion of larger amounts of GBL has been reported, although this still remains unclear [24]. 
Anyway, cases in which GBL ingestion has occurred will likely readily have high GHB blood levels and 
although the ± 10 % conversion of GBL to GHB may somewhat falsely elevate the quantitative result of GHB, 
this will likely have no relevance, neither in the forensic context, nor in the clinical setting [24,53]. 
 
3.2.3 Stability  
The stability of GHB in DBS was thoroughly investigated as previous studies reported an increase in GHB 
concentration during preservation of blood samples withdrawn on certain anti-coagulants [35,42]. So, to 
investigate the short-term stability of GHB in DBS samples on Whatman 903 filter paper, we evaluated low and 
high concentration levels (n=3) at different preservation temperatures (room temperature, 4 and -20 °C). Table 2 
shows that GHB in DBS at both low and high concentration levels is stable when stored for at least one week at 
room temperature, 24 h at 4 °C and 14 days at -20 °C, as the mean percentages were within the pre-defined 15 % 
limits. Based on these results, the collection of blood containing GHB on filter paper may result in a better 
storage manner of blood samples. Further examination is recommended to evaluate whether DBS are indeed an 
alternative and reliable way for routinely storing suspicious blood samples over a longer period of time. 
Furthermore, although in this study the DBS were dried for minimum 4 hours at room temperature before 
analysis, in compliance with the manufacturer’s recommendations, a shorter drying time of 2 hours is also 
possible if needed. 
 
Re-injection of processed samples after a waiting period of 24 h to verify autosampler-stability of the derivatized 
extracts proved to be no problem as nearly no differences in peak area ratio were seen (RSD < 2.1 %). Also the 
stability of processed samples stored for one week at -20 °C was acceptable (RSD < 2.2 %). Stock solutions 
were stable for minimum 14 days preserved at -20 °C and after 3 freeze-thaw cycles. 
 
3.3 Application 
 
Besides the screening and subsequent confirmation of positive findings with GC-MS and HPLC-DAD of blood 
and urine samples, also DBS prepared from the blood samples of two young men suspected of drug intake were 
analyzed with the described method. Results for the routine investigation of a blood sample of one young man 
led to the confirmation of the presence of alcohol (1.42 pro mille), cocaine (benzoylecgonine), cannabinoids, 
MDMA and ketamine. By analyzing the DBS, a GHB concentration of less than 1 µg/ml was found (Fig. 2a). In 
the blood of the other young man, alcohol (0.73 pro mille), cannabinoids and MDMA were present. The latter 
young man was also positive for GHB abuse as a 44.4 µg/ml GHB concentration was found by analyzing the 
DBS (Fig. 2b). This positive and negative result were confirmed by analyzing the whole blood samples for GHB 
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with our previously published method [26], suggesting that our newly developed method may be applicable in 
routine samples in a toxicological laboratory for screening purposes, as well as for the confirmation of the 
presence of GHB in whole blood samples. Interesting to note in this respect is that analysis of these DBS 5 
months later (storage at -20 °C) yielded similar results.  
 
4. CO1CLUSIO1 
 
A sensitive and accurate GC-MS method was developed for the determination of GHB in whole blood samples 
spot on Whatman 903 filter paper. The DBS sample procedure has advantages as to the conventional blood 
collection, such as easy to handle and no specific storage requirements. Especially in the case of GHB, where an 
increase in GHB concentrations during preservation of whole blood cannot be excluded, flexibility in storage 
conditions is of interest. Furthermore, as the detection window is limited, it is important that samples are 
obtained as early as possible after ingestion. By facilitating this, DBS may consequently represent an alternative 
in forensic and clinical cases where there is a suspicion of illicit use of GHB, in case of DUID or when a DFSA 
is presumed.  
Our LLOQ of 2 µg/ml is well below the proposed cut-off levels of 4 and 5 µg/ml for blood samples, so this 
method provides enough sensitivity to distinguish between endogenous and exogenously-administered GHB, 
which is of major concern for the toxicological interpretation of clinical and forensic samples.  
Finally, our approach of direct derivatization “on spot” may also be suitable for the determination of other 
compounds which impose extraction problems.  
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FIGURE LEGE1DS  
 
Fig. 1 Representative chromatograms of derivatized extracts of (a) a blank DBS spiked with IS at 10 µg/ml and 
(b) a DBS spiked with GHB at 2 µg/ml (LLOQ) and IS at 10 µg/ml, analyzed with GC-MS in the EI-SIM mode 
 
 
Fig. 2 Chromatograms obtained when analyzing the derivatized extracts of DBS from two possible GBL-users 
with GC-EI-MS in the SIM mode with (a) a GHB concentration less than 1 µg/ml in the first sample and (b) a 
GHB concentration of 44.4 µg/ml in the second sample 
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TABLES 
Table 1 
Validation data for the determination of GHB in DBS using GC-EI-MS 
 
a Calibration and sensitivity data 
 
 
LOD 
(µg/ml) 
 
LLOQ 
(µg/ml) 
 
Slope 
n=6 mean ±SD 
[ 95 % CI] 
 
 
Intercept 
n=6 mean ±SD 
 [ 95 % CI] 
 
Linear range 
(µg/ml) 
 
R
2
 
 
 
1  
 
 
2  
 
0.087 ±0.004 
[0.083 – 0.090] 
 
 
-0.012 ±0.03 
[-0.036 – 0.011] 
 
2-100 
 
1.000 
  
 
b Intra- and inter-batch precision (expressed as relative standard deviation) and accuracy (calculated as the 
percentage of the nominal concentration) determined at low, medium and high GHB concentrations in DBS 
 
 
Nominal 
concentration 
(µg/ml) 
 
 
Found 
concentration 
(µg/ml) 
 
Intra-batch 
precision 
(%RSD, n=5) 
 
Inter-batch 
precision 
(%RSD, n=6) 
 
Accuracy 
(%, n=6) 
 
2 
 
10 
 
100 
 
1.93 
 
9.49 
 
108.87 
 
4.5 
 
6.2 
 
8.1 
 
 
18.6
*
 
 
12.9 
 
3.0 
 
 
96 
 
95 
 
109 
 
          * 
Negatively influenced by one value, which was statistically just not an outlier 
 
Table 2 
Stability data of GHB in DBS, stored at room temperature up to 7 days, at 4 °C up to 24 h and at -20 °C up to 14 days, 
presented as the percentage of the results obtained when analyzed after 4 h of drying, which is the recommended drying 
time according to the manufacturer 
 
Room temperature 4°C -20°C 
 
 
 
 
Time                           
 
Low              High  
 
    n=3; mean ±SD   
 
 
 
 
Time 
 
Low              High 
 
     n=3; mean ±SD 
 
 
 
 
Time 
 
Low              High 
 
     n=3; mean ±SD   
 
2 h  
 
8 h 
 
12 h 
 
24 h 
 
48 h 
 
7 days 
 
 
98.2 ± 5.8   101.0 ± 12.0 
 
95.2 ± 7.1   107.0 ± 9.2 
 
96.4 ± 4.0   107.3 ± 10.8 
 
95.1 ± 4.6   105.4 ± 5.2 
 
98.1 ± 7.7   102.8 ± 2.9 
 
95.5 ± 2.6   101.9 ± 6.3 
 
 24 h  
 
97.2 ± 6.8   106.1 ± 13.8 
 
24 h 
 
7 days 
 
14 days 
 
 
 
 
94.1 ± 3.9    101.2 ± 9.2 
 
99.1 ± 5.4    104.4 ± 3.5 
 
99.8 ± 7.2    112.6 ± 5.1 
 
 
 
 
 
 


